Israeli Biotech Company Granted US Patent for Kidney Cancer Test

(Shutterstock)

 Print Email0 Comments

Feb 22, 2016

Related:

• Israeli innovation
• Israeli medical
• Rosetta Genomics

 Share Tweet Email

Israeli biotech Rosetta Genomics has been granted a US patent for its ability to differentiate between four types of kidney cancer.

Israeli biotech Rosetta Genomics has been granted a US patent for its gene signature method of distinguishing four different types of kidney cancer. The molecular diagnostic test recognizes the profile of 29 microRNAs that are expressed in patients with renal cancer.
http://www.rosettagx.com/files/press_releases/2016/012516_ROSG_Kidney_Tumor_Classification_Patent_FINAL.pdf

By: Michael Ordman

Click here for all of this week’s Good News from Israel.